Windtree Therapeutics Inc (NASDAQ: WINT) Is Worth A Look At Current Prices?

During the last session, Windtree Therapeutics Inc (NASDAQ:WINT)’s traded shares were 0.48 million, with the beta value of the company hitting 0.76. At the end of the trading day, the stock’s price was $0.57, reflecting an intraday gain of 3.64% or $0.02. The 52-week high for the WINT share is $737.43, that puts it down -129273.68 from that peak though still a striking 8.77% gain since the share price plummeted to a 52-week low of $0.52. The company’s market capitalization is $2.08M, and the average intraday trading volume over the past 10 days was 12.63 million shares, and the average trade volume was 4.57 million shares over the past three months.

Windtree Therapeutics Inc (WINT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. WINT has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.

Windtree Therapeutics Inc (NASDAQ:WINT) trade information

Windtree Therapeutics Inc (WINT) registered a 3.64% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.64% in intraday trading to $0.57, hitting a weekly high. The stock’s 5-day price performance is -5.63%, and it has moved by -30.49% in 30 days. Based on these gigs, the overall price performance for the year is -99.66%. The short interest in Windtree Therapeutics Inc (NASDAQ:WINT) is 0.18 million shares and it means that shorts have 0.8 day(s) to cover.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 75.28%.

WINT Dividends

Windtree Therapeutics Inc is due to release its next quarterly earnings on 2025-Apr-15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Windtree Therapeutics Inc (NASDAQ:WINT)’s Major holders

Windtree Therapeutics Inc insiders own 0.01% of total outstanding shares while institutional holders control 1.39%, with the float percentage being 1.39%.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.